Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144697 | 0.93 | ABCB11 (0.62) | ABCB11CCR1SIGMAR1MCHR1KCNH2 | |
| SCHEMBL30172121 | 0.84 | ABCB11 (0.61) | ABCB11CCR3SIGMAR1MCHR1KCNH2 | |
| SCHEMBL3140426 | 0.83 | ABCB11 (0.63) | ABCB11CCR1SIGMAR1CCR5 | |
| SCHEMBL3807474 | 0.83 | CCR1 (0.83) | ABCB11CCR1CCR3SIGMAR1MCHR1 | |
| SCHEMBL30172144 | 0.83 | CCR1 (0.83) | ABCB11CCR1CCR3SIGMAR1MCHR1 | |
| SCHEMBL1682975 | 0.83 | CCR1 (0.83) | ABCB11CCR1CCR3SIGMAR1MCHR1 | |
| SCHEMBL3140521 | 0.83 | ABCB11 (0.70) | ABCB11CCR1SIGMAR1MCHR1 | |
| SCHEMBL3150012 | 0.82 | ABCB11 (0.61) | ABCB11CCR1CCR3SIGMAR1MCHR1 | |
| SCHEMBL3145066 | 0.82 | ABCB11 (0.62) | ABCB11CCR1SIGMAR1MCHR1CCR5 | |
| SCHEMBL3135889 | 0.81 | ABCB11 (0.61) | ABCB11CCR1CCR3SIGMAR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | ASTRAZENECA AB (SE) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081692-A1 | Novel 1-Benzyl-4-Piperidinamines that are Useful in the Treatment of COPD and Asthma | CCR1, CCR4, CCR10 | ABCB11 477/4885CCR1 1/4885CCR3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.